Xometry Surges 17% Post-Earnings as Analysts Chase Targets Higher

XMTR has just delivered one of its sharpest single-session moves in recent memory, jumping 16.5% on November 3 after Q3 results, and the Street's response has been immediate and uniform.

Seven analysts lifted their price targets on November 4 alone, all maintaining positive ratings. JP Morgan raised its target from $120 to $140, keeping Overweight, while Citigroup moved from $110 to $132, maintaining Buy. Wedbush lifted to $140 from $126 and Rosenblatt to $130 from $120. The direction is unambiguous: every firm that updated after the print moved higher, with no downgrades and no rating cuts in the batch. The mean consensus target now sits at $116, though several of the freshest targets cluster between $130 and $140, suggesting the consensus number will catch up as more firms update. With the stock at $111, the gap between current price and the most bullish fresh targets is around 26%. RBC kept its more cautious Sector Perform rating but still lifted to $117, the lone note of restraint in an otherwise bullish chorus.

The bull case centres on scale validation: marketplace revenue reportedly grew 45% year on year in Q2, full-year guidance was raised to 33-34% growth, and the company now counts more than 2,000 accounts spending above $50K annually. The Siemens partnership, which embeds Xometry into major CAD workflows without a revenue share arrangement, adds a distribution angle the bears had not fully priced. The bear case has not vanished. Macro exposure remains real, commodity swings can distort the quoting algorithm, and the top 200 accounts represent a concentration risk that matters if enterprise spending softens. EV/EBITDA has expanded sharply in one day, reaching 65.7x, and the PE ratio is near 89x, leaving little room for execution stumbles. EPS surprise ranks in just the 10th percentile of the ORTEX universe, a reminder that beating estimates has not been a consistent habit, though forward EPS momentum scores rank in the 92nd percentile over 30 days and the 89th over 90 days, reflecting the recent upward revision cycle.

The lending market confirms that short sellers were caught off-side. Short interest came into the print at 7.7% of the free float, after falling roughly 14% over the prior month as bears trimmed ahead of results. Borrow availability is comfortable at 241%, meaning there are more than two shares available to borrow for every share currently shorted, well clear of squeeze territory. Cost to borrow is a negligible 0.51%. What the options market was pricing ahead of the print, as flagged in Monday's earnings preview note, was genuine hedging demand: the put/call ratio had jumped to 0.32 against a 20-day mean of 0.14, a z-score of 3.2 that now reads as protective positioning around a known event rather than structural bearishness. The PCR has eased slightly but remains elevated relative to the quiet weeks of October when it barely broke 0.13.

Wikipedia attention data from ORTEX Alt Data adds texture to the retail angle. The attention signal, measured as a z-score of daily English Wikipedia article views and ORTEX stock page visitors against the prior 90 days, registered 5.4 as of October 19, well above normal. This measures attention, not revenue, but the reading suggests retail engagement with the XMTR story was building before the print, which may help explain the volume dynamic on the day.

Institutional ownership provides a stable backdrop. PRIMECAP Management holds 11.6% of shares, with FMR (Fidelity) adding 780,615 shares in the most recently reported quarter to reach 6.8%. BlackRock added 339,609 shares to reach 6.7%. Notably, Siemens AG appears on the holder register with just under 1.05 million shares, a position first reported as of June 30, reinforcing that the partnership carries real economic alignment and not just a commercial agreement. No 13D activists are on the register. Insider sales over the past 90 days total a net negative $6.2 million, with the CEO and CTO both selling under pre-arranged 10b5-1 plans in October, a compensation mechanism rather than a discretionary signal.

The next earnings date is pencilled in for February 24, 2027. Between now and then, the question is whether the analyst target upgrades translate into fresh institutional buying, and whether short interest, still at 7.7% of float, continues its gradual decline or stabilises as new shorts probe the elevated valuation.